+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anal Cancer - Pipeline Insight, 2021

  • ID: 5305168
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Genentech
  • Inovio Pharmaceuticals
  • Merck KGaA
This “Anal Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Anal Cancer Understanding

Anal Cancer: Overview

Anal cancer is a rare condition, although its incidence has been increasing over the past several decades, particularly in women. The majority of anal cancers are squamous cell cancers and are linked with human papilloma virus (HPV) infection. Many anal cancers are found early because they are in a location that your physician can easily see and reach. Diagnosis is often made when people with any of the above symptoms undergo an anal exam. Anal cancer may also be found incidentally during yearly physical exams that include a digital rectal exam. The rectal exam is performed to check the rectum, prostate or other pelvic organs. Anal cancers can also be found when a person has a preventive colorectal screening test (such as a colonoscopy).

"Anal Cancer - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anal Cancer pipeline landscape is provided which includes the disease overview and Anal Cancer treatment guidelines. The assessment part of the report embraces, in depth Anal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Anal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Anal Cancer.
Anal Cancer Emerging Drugs Chapters

This segment of the Anal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anal Cancer Emerging Drugs

Atezolizumab: Genentech

Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs).[16] PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer.[16] Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. The drug is in phase 2 of clinical trials for the treatment of anal cancer,

Avelumab: Merck KGaA

Avelumab is a human anti-programmed death ligand-1 (PD-L1) antibody. Avelumab has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models. The drug is in phase I/II of clinical trials for the treatment of anal cancer.

Anal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Anal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Anal Cancer

There are approx. 5+ key companies which are developing the therapies for Anal Cancer. The companies which have their Anal Cancer drug candidates in the mid to advanced stage, i.e. phase II include, Genentech.

Phases

This report covers around 5+ products under different phases of clinical development like
  • Late-stage products (phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
Route of Administration

Anal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
Molecule Type

Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anal Cancer drugs.

Anal Cancer Report Insights
  • Anal Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Anal Cancer Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Anal Cancer drugs?
  • How many Anal Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anal Cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anal Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Anal Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Genentech
  • Merck KGaA
  • Inovio Pharmaceuticals
Key Products
  • Atezolizumab
  • Avelumab
  • VGX 3100
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Genentech
  • Inovio Pharmaceuticals
  • Merck KGaA
Introduction

Executive Summary

Anal Cancer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Anal Cancer - Analytical Perspective

In-depth Commercial Assessment
  • Anal Cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends
Anal Cancer Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Ceftobiprole medocaril: Basilea pharmaceutica
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Anal Cancer Key Companies

Anal Cancer Key Products

Anal Cancer- Unmet Needs

Anal Cancer- Market Drivers and Barriers

Anal Cancer- Future Perspectives and Conclusion

Anal Cancer Analyst Views

Anal Cancer Key Companies

Appendix

List of Tables
Table 1 Total Products for Anal Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Anal Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Genentech
  • Merck KGaA
  • Inovio Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll